Prohias MJA, Luperon LD, López GA, Claro VR

Idioma: Español
Referencias bibliográficas: 19
Paginas: 1-5
Archivo PDF: 150.08 Kb.

RESUMEN

La mortalidad de los pacientes oncológicos se ha reducido significativamente debido a los avances en el diagnóstico precoz y el tratamiento del cáncer. No obstante, para mejorar el pronóstico se deben prevenir, diagnosticar y tratar las complicaciones derivadas de los tratamientos oncológicos mediante la constitución de equipos multidisciplinarios entre oncólogos y cardiólogos. Se presenta la experiencia de la cardioncología en el Hospital Hnos. Ameijeiras como modelo de organización en un hospital terciario potencialmente aplicable a hospitales secundarios en el país con sus resultados en el diagnóstico y tratamiento de la cardiotoxicidad y en el seguimiento de los sobrevivientes de cáncer.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977–1010.

2. Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet. 2014;383:549–557.

3. Freeman AM, Herrmann J, Iliescu C, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015; 65:2739–2746.

4. Fiuza M, Ribeiro L, Magalhães A, et al. Organization and implementation of a cardio-oncology program. Rev Port Cardiol. 2016; 35(9):485-94.

5. Barros-Gomes S, Herrmann J, Mulvagh SL, Lerman A, Lin G, Villarraga HR. Rationalefor setting up a cardio-oncology unit: our experience at Mayo Clinic. Cardio-Oncology. 2016; 2:1–9.

6. Mehta LS,Watson K E, Barac A et al: Cardiovascular disease and breast cancer Where these entities Intersect. Circulation. 2018; 137: e1-e35.

7. Gujral DM, Manisty C, Lloyd G, et al. Organisation & models of cardio oncology clinics. Int J Cardiol 2016; 214:381–2.

8. Sulpher J, Mathur S, Graham N, et al. Clinical experience of patients referred to a multidisciplinary Cardiac Oncology Clinic: an observational study. J Oncol. 2015; 671232.

9. Okwuosa T, Barac A. Burgeoning cardio-oncology programs: challenges and opportunities for early career cardiologists/faculty directors. J Am Coll Cardiol. 2015; 66:1193.

10. Snipelisky D,Yoon Park J, Lerman A et al. How to develop a cardioncology clinic. Heart Failure Clin. 2017; (13) 347-359.

11. Lopez Fernandez T, Martin Garcia A, Santaballa Beltran A et al. Cardio-Onco-Hematologia en la práctica clínica. Rev Esp Cardiol 2017; 70(6)474-486.

12. Pavo N, Raderer M, Hülsmann M, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101:1874–1880.

13. Wang L, Tan TC, Halpern EF, et al. Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy. Am J Cardiol. 2015;116:442–446.

14. Parent S, Pituskin E, Paterson DI. The cardio-oncology program: a multidisciplinary approach to the care of cancer patients with cardiovascular disease. Can J Cardiol. 2016; 32:847–851.

15. Lenihan DJ, Hartlage G, DeCara J, et al. Cardio-oncology training: A proposal from the international cardioncology society and canadian cardiac oncology network for a new multidisciplinary specialty. J Card Fail. 2016; 22:465–471.

16. Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin Proc. 2016;91:81–83.

17. Barac A, Murtagh G, Carver JR, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015; 65: 2739–46.

18. Herrmann J, Yang EH, Iliescu CA, et al. Vascular toxicities of cancer therapies: The old and the new – an evolving avenue. Circulation. 2016; 133:1272–1289.

19. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016; 118:1008–1020.